← Back to front page
United States · Platforms & data · The Motley Fool

Billionaire Stanley Druckenmiller Added to Revolution Medicines Before Its FDA Win. Is the Stock Still a Buy After a 134% Run?

Published by The Motley Fool · United States 1 h ago

The biotech has experienced a pullback in recent weeks.

Read the full article on The Motley Fool Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.fool.com)

Also worth reading

MarketBeat

Sierra Bancorp (NASDAQ:BSRR) Price Target Raised to $48.50

 Seeking Alpha

Mapletree Industrial Trust reports Q2 results

 MarketWatch

CoreWeave and other AI stocks rise as Anthropic restores the market’s faith in sustained spending

 Investing.com

CBIZ stockholders approve merger with Viking ParentCo at special meeting

 Benzinga

Myro (MYRO) Price Prediction: 2025, 2026, 2030

 Morningstar

Novartis Raises Guidance After Trial Setbacks Hit Profit